ID   Daudi
AC   CVCL_0008
SY   DAUDI; NK-10A; NK-10a; NK 10a; NK10a; N; GM03190; GM3190; GM03190A; GM17346
DR   BTO; BTO:0001561
DR   CLO; CLO_0002708
DR   CLO; CLO_0013411
DR   CLO; CLO_0013740
DR   CLO; CLO_0050991
DR   EFO; EFO_0002169
DR   MCCL; MCC:0000141
DR   CLDB; cl993
DR   CLDB; cl994
DR   CLDB; cl995
DR   CLDB; cl996
DR   CLDB; cl997
DR   CLDB; cl998
DR   CLDB; cl999
DR   CLDB; cl5181
DR   AddexBio; C0003010/4669
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CCL-213
DR   ATCC; CRL-7917
DR   BCRC; 60192
DR   BioGRID_ORCS_Cell_line; 1081
DR   BioSample; SAMN00808283
DR   BioSample; SAMN01821546
DR   BioSample; SAMN01821623
DR   BioSample; SAMN03472413
DR   BioSample; SAMN10987948
DR   cancercelllines; CVCL_0008
DR   CCRID; 1101HUM-PUMC000134
DR   CCRID; 1102HUM-NIFDC00053
DR   CCRID; 3101HUMTCHu140
DR   CCRID; 4201HUM-CCTCC00097
DR   CCTCC; GDC0097
DR   Cell_Model_Passport; SIDM00845
DR   CGH-DB; 9195-4
DR   ChEMBL-Cells; CHEMBL3307579
DR   ChEMBL-Targets; CHEMBL614281
DR   CLS; 302009
DR   Coriell; GM03190
DR   Coriell; GM17346
DR   Cosmic; 687838
DR   Cosmic; 906831
DR   Cosmic; 919135
DR   Cosmic; 929815
DR   Cosmic; 931102
DR   Cosmic; 932762
DR   Cosmic; 991548
DR   Cosmic; 996304
DR   Cosmic; 998716
DR   Cosmic; 1019315
DR   Cosmic; 1037701
DR   Cosmic; 1070708
DR   Cosmic; 1071878
DR   Cosmic; 1086326
DR   Cosmic; 1093789
DR   Cosmic; 1118470
DR   Cosmic; 1176616
DR   Cosmic; 1191690
DR   Cosmic; 1517663
DR   Cosmic; 1995384
DR   Cosmic; 2649240
DR   Cosmic; 2759407
DR   Cosmic; 2760061
DR   Cosmic; 2814537
DR   Cosmic; 2815216
DR   Cosmic; 2823073
DR   Cosmic-CLP; 906831
DR   dbMHC; 48767
DR   DepMap; ACH-000786
DR   DSMZ; ACC-78
DR   DSMZCellDive; ACC-78
DR   ECACC; 85011437
DR   ECACC; 94071449
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 906831
DR   GEO; GSM99381
DR   GEO; GSM862859
DR   GEO; GSM862860
DR   GEO; GSM862861
DR   GEO; GSM862862
DR   GEO; GSM886973
DR   GEO; GSM888042
DR   GEO; GSM960117
DR   GEO; GSM960118
DR   GEO; GSM960119
DR   GEO; GSM960120
DR   GEO; GSM1374459
DR   GEO; GSM1669726
DR   GEO; GSM3150242
DR   IARC_TP53; 143
DR   IARC_TP53; 21144
DR   ICLC; HTL95024
DR   IGRhCellID; Daudi
DR   IHW; IHW09366
DR   IPD-IMGT/HLA; 10471
DR   IZSLER; BS TCL 104
DR   JCRB; JCRB9071
DR   KCB; KCB 2012116YJ
DR   KCLB; 10213
DR   LiGeA; CCLE_233
DR   LINCS_LDP; LCL-2018
DR   Lonza; 490
DR   NCBI_Iran; C112
DR   PharmacoDB; Daudi_283_2019
DR   PRIDE; PXD004181
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0008
DR   PubChem_Cell_line; CVCL_0008
DR   RCB; RCB1640
DR   TKG; TKG 0362
DR   Wikidata; Q54828579
RX   CelloPub=CLPUB00447;
RX   PubMed=170370;
RX   PubMed=216485;
RX   PubMed=2052620;
RX   PubMed=2140233;
RX   PubMed=2470097;
RX   PubMed=2985879;
RX   PubMed=2998993;
RX   PubMed=3026973;
RX   PubMed=3034807;
RX   PubMed=3080238;
RX   PubMed=3116544;
RX   PubMed=3159941;
RX   PubMed=3518877;
RX   PubMed=3785169;
RX   PubMed=3874327;
RX   PubMed=3905596;
RX   PubMed=4122458;
RX   PubMed=4174339;
RX   PubMed=4178827;
RX   PubMed=4321974;
RX   PubMed=4364259;
RX   PubMed=4878906;
RX   PubMed=5021706;
RX   PubMed=6186604;
RX   PubMed=6200433;
RX   PubMed=6231253;
RX   PubMed=6286763;
RX   PubMed=6500159;
RX   PubMed=6547209;
RX   PubMed=6582512;
RX   PubMed=6592381;
RX   PubMed=6806672;
RX   PubMed=6935474;
RX   PubMed=6954533;
RX   PubMed=7316467;
RX   PubMed=7849311;
RX   PubMed=8197130;
RX   PubMed=8301159;
RX   PubMed=8515068;
RX   PubMed=8558913;
RX   PubMed=8558920;
RX   PubMed=8847894;
RX   PubMed=9192833;
RX   PubMed=9473234;
RX   PubMed=9510473;
RX   PubMed=9685479;
RX   PubMed=9737686;
RX   PubMed=9738977;
RX   PubMed=9973220;
RX   PubMed=10739008;
RX   PubMed=11021758;
RX   PubMed=11226526;
RX   PubMed=11894933;
RX   PubMed=12145705;
RX   PubMed=12967475;
RX   PubMed=14504097;
RX   PubMed=15028022;
RX   PubMed=19358282;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=22460905;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29892436;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=35839778;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=DAUDI
WW   https://www.proteinatlas.org/learn/cellines
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/d/cell-lines-detail-87.html
WW   https://tcpaportal.org/mclp/
CC   Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Human variation panel.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African; Kenyan.
CC   Doubling time: 23.7 hours (PubMed=8847894); ~48 hours (DSMZ=ACC-78).
CC   HLA typing: A*01:02,66:01; B*35:01,58:01; C*03:02,06:02; DQA1*01:03,01:03; DQB1*06:13,06:13; DRB1*13:02,03:27 (PubMed=25960936).
CC   HLA typing: A*01:02,66:01; B*58:01,58:01; C*03:02,06:02 (PubMed=26589293).
CC   HLA typing: A*01:02,66:01; B*58:01:01:01,58:02:01; C*03:02:02:01,06:02; DPA1*01:03:01,02:01:01:01; DPB1*02:01:02:01,106:01; DQA1*01:02,01:03; DQB1*06:04:01,06:02; DRB1*13:01:01,13:02:01; DRB3*02:02,03:01:01; DRB6*02 (IPD-IMGT/HLA=10471).
CC   HLA typing: A*01:02,66:01:01; B*58:01:01,58:02:01; C*03:02:02,06:02:01; DPA1*01:03:01,02:01:01; DPB1*02:01:02,106:01; DQA1*01:02:01,01:03:01; DQB1*06:09:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*13:01:01,13:02:01 (DSMZCellDive=ACC-78).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=3116544; PubMed=6806672).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (PubMed=8197130; PubMed=11894933; Cosmic-CLP=906831; DepMap=ACH-000786).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (ATCC=CCL-213).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (Cosmic-CLP=906831; DepMap=ACH-000786).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=91.6%; Native American=0.12%; East Asian, North=2.24%; East Asian, South=0%; South Asian=1.3%; European, North=0%; European, South=4.74% (PubMed=30894373).
CC   Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620.
CC   Misspelling: Duadi; Note=Occasionally.
CC   Discontinued: ATCC; CRL-7917; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): AddexBio=C0003010/4669; ATCC=CCL-213; CCRID; Cosmic-CLP=906831; DSMZ=ACC-78; KCLB=10213; PubMed=25877200; RCB=RCB1640; TKG=TKG 0362
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 10,12
ST   D18S51: 16,18
ST   D19S433: 12,14
ST   D21S11: 34,35
ST   D2S1338: 17,24
ST   D3S1358: 16,18
ST   D5S818: 8,13
ST   D7S820: 8,10
ST   D8S1179: 14
ST   FGA: 21,26
ST   Penta D: 10,12
ST   Penta E: 7,9 (ATCC=CCL-213; DSMZ=ACC-78; PubMed=25877200)
ST   Penta E: 9 (CCRID)
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   16Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 48
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In misc. document) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda; USA (1992).
//
RX   PubMed=170370; DOI=10.1099/0022-1317-28-2-207;
RA   Adams A., Strander H., Cantell K.;
RT   "Sensitivity of the Epstein-Barr virus transformed human lymphoid cell
RT   lines to interferon.";
RL   J. Gen. Virol. 28:207-217(1975).
//
RX   PubMed=216485;
RA   Higgins N.P., Strauss B.S.;
RT   "Differences in the ability of human lymphoblastoid lines to exclude
RT   bromodeoxyuridine and in their sensitivity to methyl methanesulfonate
RT   and to incorporated [3H]thymidine.";
RL   Cancer Res. 39:312-320(1979).
//
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2470097; DOI=10.1073/pnas.86.9.3257; PMCID=PMC287109;
RA   Shtivelman E., Henglein B., Groitl P., Lipp M., Bishop J.M.;
RT   "Identification of a human transcription unit affected by the variant
RT   chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:3257-3260(1989).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=2998993;
RA   Steel C.M., Morten J.E.N., Foster E.;
RT   "The cytogenetics of human B lymphoid malignancy: studies in Burkitt's
RT   lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell
RT   lines.";
RL   IARC Sci. Publ. 60:265-292(1985).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3034807; DOI=10.1002/ijc.2910390622;
RA   Ohno H., Fukuhara S., Takahashi R., Mihara K.-i., Sugiyama T., Doi S.,
RA   Uchino H., Toyoshima K.;
RT   "c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma
RT   cell line carrying a t(14;18) chromosomal translocation.";
RL   Int. J. Cancer 39:785-788(1987).
//
RX   PubMed=3080238;
RA   Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.;
RT   "Expression of surface antigens during the cell cycle in different
RT   growth phases of American and African Burkitt's lymphoma cell lines.";
RL   Cancer Res. 46:1182-1188(1986).
//
RX   PubMed=3116544; DOI=10.1073/pnas.84.19.6835; PMCID=PMC299179;
RA   Haluska F.G., Tsujimoto Y., Croce C.M.;
RT   "The t(8;14) chromosome translocation of the Burkitt lymphoma cell
RT   line Daudi occurred during immunoglobulin gene rearrangement and
RT   involved the heavy chain diversity region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6835-6839(1987).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3785169; DOI=10.1128/mcb.6.5.1374-1378.1986; PMCID=PMC367660;
RA   Dron M., Modjtahedi N., Brison O., Tovey M.G.;
RT   "Interferon modulation of c-myc expression in cloned Daudi cells:
RT   relationship to the phenotype of interferon resistance.";
RL   Mol. Cell. Biol. 6:1374-1378(1986).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=3905596;
RA   Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C.,
RA   Dore J.-F., Lenoir G.M.;
RT   "Immunophenotypic classification of 28 Burkitt cell lines with
RT   monoclonal antibodies and reagent selection for bone-marrow purging.";
RL   IARC Sci. Publ. 60:447-452(1985).
//
RX   PubMed=4122458; DOI=10.1002/ijc.2910100108;
RA   Klein G., Dombos L., Gothoskar B.;
RT   "Sensitivity of Epstein-Barr virus (EBV) producer and non-producer
RT   human lymphoblastoid cell lines to superinfection with EB-virus.";
RL   Int. J. Cancer 10:44-57(1972).
//
RX   PubMed=4174339;
RA   Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H.,
RA   Clifford P.;
RT   "Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and
RT   in derived culture lines.";
RL   Cancer Res. 28:1300-1310(1968).
//
RX   PubMed=4178827; DOI=10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M;
RA   Nadkarni J.S., Nadkarni J.J., Clifford P., Manolov G., Fenyo E.-M.,
RA   Klein E.;
RT   "Characteristics of new cell lines derived from Burkitt lymphomas.";
RL   Cancer 23:64-79(1969).
//
RX   PubMed=4321974;
RA   Maurer B.A., Imamura T., Wilbert S.M.;
RT   "Incidence of EB virus-containing cells in primary and secondary
RT   clones of several Burkitt lymphoma cell lines.";
RL   Cancer Res. 30:2870-2875(1970).
//
RX   PubMed=4364259; DOI=10.1002/ijc.2910110210;
RA   Klein G., Dombos L.;
RT   "Relationship between the sensitivity of EBV-carrying lymphoblastoid
RT   lines to superinfection and the inducibility of the resident viral
RT   genome.";
RL   Int. J. Cancer 11:327-337(1973).
//
RX   PubMed=4878906; DOI=10.1084/jem.128.5.1011; PMCID=PMC2138555;
RA   Klein G., Pearson G.R., Nadkarni J.S., Nadkarni J.J., Klein E.,
RA   Henle G., Henle W., Clifford P.;
RT   "Relation between Epstein-Barr viral and cell membrane
RT   immunofluorescence of Burkitt tumor cells. I. Dependence of cell
RT   membrane immunofluorescence on presence of EB virus.";
RL   J. Exp. Med. 128:1011-1020(1968).
//
RX   PubMed=5021706; PMCID=PMC1407864;
RA   van Furth R., Gorter H., Nadkarni J.S., Nadkarni J.J., Klein E.,
RA   Clifford P.;
RT   "Synthesis of immunoglobulins by biopsied tissues and cell lines from
RT   Burkitt's lymphoma.";
RL   Immunology 22:847-857(1972).
//
RX   PubMed=6186604; DOI=10.1007/BF00364753;
RA   de Preval C., Mach B.;
RT   "The absence of beta 2-microglobulin in Daudi cells: active gene but
RT   inactive messenger RNA.";
RL   Immunogenetics 17:133-140(1983).
//
RX   PubMed=6200433; DOI=10.1007/BF00364762;
RA   Brodsky F.M.;
RT   "A matrix approach to human class II histocompatibility antigens:
RT   reactions of four monoclonal antibodies with the products of nine
RT   haplotypes.";
RL   Immunogenetics 19:179-194(1984).
//
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
//
RX   PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=6547209; DOI=10.1038/309592a0;
RA   Rabbitts T.H., Forster A., Hamlyn P.H., Baer R.;
RT   "Effect of somatic mutation within translocated c-myc genes in
RT   Burkitt's lymphoma.";
RL   Nature 309:592-597(1984).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6592381; DOI=10.1093/jnci/73.4.841;
RA   Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F.,
RA   Lenoir G.M.;
RT   "Distinct reactivity of Burkitt's lymphoma cell lines with eight
RT   monoclonal antibodies correlated with the ethnic origin.";
RL   J. Natl. Cancer Inst. 73:841-847(1984).
//
RX   PubMed=6806672; DOI=10.1038/298474a0;
RA   Lenoir G.M., Preud'homme J.-L., Bernheim A., Berger R.;
RT   "Correlation between immunoglobulin light chain expression and variant
RT   translocation in Burkitt's lymphoma.";
RL   Nature 298:474-476(1982).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C.F.M., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=8197130; DOI=10.1073/pnas.91.11.4751; PMCID=PMC43866;
RA   Bicknell D.C., Rowan A.J., Bodmer W.F.;
RT   "Beta 2-microglobulin gene mutations: a study of established
RT   colorectal cell lines and fresh tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994).
//
RX   PubMed=8301159; DOI=10.1089/jir.1993.13.377;
RA   Dron M., Tovey M.G.;
RT   "Interferon-resistant Daudi cells are deficient in
RT   interferon-alpha-induced ISGF3 alpha activation, but remain sensitive
RT   to the interferon-alpha-induced increase in ISGF3 gamma content.";
RL   J. Interferon Res. 13:377-383(1993).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=8847894;
RA   Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K.,
RA   Nakamura H., Amakawa R., Ohno H.;
RT   "Sensitivity to dexamethasone and absence of bcl-2 protein in
RT   Burkitt's lymphoma cell line (Black93) derived from a patient with
RT   acute tumor lysis syndrome: comparative study with other BL and non-BL
RT   lines.";
RL   Leukemia 10:1592-1603(1996).
//
RX   PubMed=9192833;
RA   Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S.,
RA   Pike S.E., Gupta G., Magrath I.T., Tosato G.;
RT   "Role of the p53 tumor suppressor gene in the tumorigenicity of
RT   Burkitt's lymphoma cells.";
RL   Cancer Res. 57:2508-2515(1997).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651; PMCID=PMC147775;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
//
RX   PubMed=9737686; DOI=10.1038/sj.leu.2401112;
RA   Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S.,
RA   Takeshita K., Takeshita A., Ohno R.;
RT   "The induction of apoptosis and cell cycle arrest by arsenic trioxide
RT   in lymphoid neoplasms.";
RL   Leukemia 12:1383-1391(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x; PMCID=PMC5921886;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G.,
RA   Magrath I.T., Bhatia K.G.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M.J., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000), 255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=11894933; DOI=10.1002/j.1460-2075.1983.tb01412.x; PMCID=PMC555120;
RA   Rosa F.M., Berissi H., Weissenbach J., Maroteaux L., Fellous M.,
RA   Revel M.;
RT   "The beta2-microglobulin mRNA in human Daudi cells has a mutated
RT   initiation codon but is still inducible by interferon.";
RL   EMBO J. 2:239-243(1983).
//
RX   PubMed=12145705; DOI=10.1038/sj.leu.2402519;
RA   Langerak A.W., Moreau E.J., van Gastel-Mol E.J., van der Burg M.,
RA   van Dongen J.J.M.;
RT   "Detection of clonal EBV episomes in lymphoproliferations as a
RT   diagnostic tool.";
RL   Leukemia 16:1572-1573(2002).
//
RX   PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x; PMCID=PMC11160262;
RA   Maesako Y., Uchiyama T., Ohno H.;
RT   "Comparison of gene expression profiles of lymphoma cell lines from
RT   transformed follicular lymphoma, Burkitt's lymphoma and de novo
RT   diffuse large B-cell lymphoma.";
RL   Cancer Sci. 94:774-781(2003).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x;
RA   Kamimura K., Hojo H., Abe M.;
RT   "Characterization of expression of protein kinase C isozymes in human
RT   B-cell lymphoma: relationship between its expression and prognosis.";
RL   Pathol. Int. 54:224-230(2004).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22885699; DOI=10.1038/nature11378; PMCID=PMC3609867;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. 3rd, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.-C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29892436; DOI=10.1098/rsos.172472; PMCID=PMC5990783;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C.,
RA   Yang H.H., Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//